Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Kyowa Kirin Co., Ltd.
  6. News
  7. Summary
    4151   JP3256000005

KYOWA KIRIN CO., LTD.

(4151)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Kyowa Kirin Co., Ltd. Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘Off’ Episodes in People Living with Parkinson’s

07/23/2021 | 10:05am EDT

Kyowa Kirin Co., Ltd. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. Istradefylline is a novel, first-in-class non-dopaminergic, adenosine A2A receptor antagonist that reduces ‘OFF’ time in people living with Parkinson’s through selective targeting of adenosine A2A receptors in the basal ganglia. Whilst dopaminergic treatment targets the dopamine receptors in the direct and indirect pathways to facilitate movement, istradefylline, as an add-on to L-Dopa, reduces the activity of the indirect pathway which suppresses movement. Therefore, it helps restore the balance within the basal ganglia.


© S&P Capital IQ 2021
All news about KYOWA KIRIN CO., LTD.
09/13KYOWA KIRIN : to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Ph..
BU
09/13Kyowa Kirin Co., Ltd. to Present Atopic Dermatitis Clinical Data from Khk4083..
CI
09/13Kyowa Kirin Initiates Phase 2 Clinical Study of G-Lasta® for the Mobilization..
CI
09/08AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercializat..
CI
09/01Kyowa Kirin Announces NDA Submission of Automated Injection Device of G-Lasta..
CI
08/17MEI PHARMA : Doses First Patient in Phase 3 Study of Zandelisib in Lymphoma Pati..
MT
08/17MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in th..
CI
08/03Kyowa Kirin Co., Ltd. Announces Earnings Results for the Second Quarter of th..
CI
08/03KYOWA KIRIN : Appendix to the Consolidated Financial Summary Fiscal 2021 Interim
PU
08/03KYOWA KIRIN : Consolidated Financial Summary Fiscal 2021 Second Quarter
PU
More news
Financials
Sales 2021 351 B 3 194 M 3 194 M
Net income 2021 51 627 M 469 M 469 M
Net cash 2021 295 B 2 677 M 2 677 M
P/E ratio 2021 42,7x
Yield 2021 1,12%
Capitalization 2 203 B 20 048 M 20 025 M
EV / Sales 2021 5,43x
EV / Sales 2022 4,92x
Nbr of Employees 5 423
Free-Float 45,8%
Chart KYOWA KIRIN CO., LTD.
Duration : Period :
Kyowa Kirin Co., Ltd. Technical Analysis Chart | 4151 | JP3256000005 | MarketScreener
Technical analysis trends KYOWA KIRIN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 4 100,00 JPY
Average target price 4 115,00 JPY
Spread / Average Target 0,37%
EPS Revisions
Managers and Directors
Masashi Miyamoto President, CEO & Representative Director
Motohiko Kawaguchi Executive Officer, Manager-Accounting & Finance
Nobuo Hanai Chairman
Mitsuo Satoh Executive Officer, GM-Research & Development
Kentaro Uryu Independent Outside Director
Sector and Competitors